

# Eligibility for Abrysvo® and nirsevimab (Beyfortus™)



## NSW RSV Prevention Program

Please distribute to all doctors, nurses and other staff in your practice or service.

### National Immunisation Program: Maternal RSV vaccine Abrysvo®

A single dose of Abrysvo should be offered year round to all pregnant women at the 28-week antenatal visit (recommended between 28 to 36 weeks gestation)

- Free under the National Immunisation Program from 3 February 2025.
- Abrysvo is the only RSV vaccine available for administration to pregnant women.
- Abrysvo can be co-administered with other antenatal vaccinations including diphtheria, tetanus and pertussis (dTpa) vaccine (also given at the 28-week antenatal visit) and influenza vaccines. For further information on co-administration see the [Australian Immunisation Handbook](#).
- Abrysvo is not recommended for use before 28 weeks until additional safety and effectiveness data is available.
- Abrysvo can be given after 36 weeks gestation however infants may not be adequately protected if they are born within 2 weeks of their mother being vaccinated. If delivery occurs within 2 weeks of the mother receiving Abrysvo, the infant is recommended to also receive nirsevimab (see below).

### NSW funded monoclonal antibody: Beyfortus™ (nirsevimab)

**Infants born on or after 17 March 2025** who meet the following eligibility criteria:

- to mothers who did not receive Abrysvo during pregnancy, **or**
- within 2 weeks of the mother receiving Abrysvo during pregnancy, **or**
- with risk conditions for severe RSV disease<sup>1</sup> regardless of maternal vaccination status, **or**
- to mothers with active malignancies or receiving chemotherapy or taking rituximab or other high-dose immunosuppressive therapy as per the [Australian Immunisation Handbook](#), **or**
- to mothers who have received Abrysvo in pregnancy but have subsequently undergone a treatment, such as cardiopulmonary bypass or extracorporeal membrane oxygenation, that has led to loss of maternal antibodies.

Eligible infants should receive nirsevimab prior to discharge from hospital.

**Children up to 24 months of age entering their second RSV season** who meet the following eligibility criteria:

- Children with risk conditions for severe RSV disease<sup>1</sup>.
- A minimum interval of 6 months is recommended between a 1st and 2nd season dose of nirsevimab.

Eligible children can receive nirsevimab through their local general practitioner (GP), Aboriginal medical service (AMS) or community health service<sup>2</sup>

**NSW RSV Vulnerable Babies Program catch-up for infants born from 1 October 2024 to 16 March 2025** who meet the following eligibility:

- Infants not protected through maternal RSV vaccination, **and**
- did not receive nirsevimab at birth, **and**
- Infants who meet one of the following eligibility criteria:
  - premature infants born less than 37 weeks gestation, **or**
  - Aboriginal and Torres Strait Islander infants, **or**
  - infants with risk conditions for severe RSV disease<sup>1</sup>.

Eligible infants can receive nirsevimab through their local GP, AMS or community health service<sup>2</sup>.

---

<sup>1</sup> **Conditions associated with increased risk of severe RSV disease** in infants and young children as recommended in the [Australian Immunisation Handbook](#) include:

- preterm birth <32 weeks gestational age
- ongoing haemodynamically significant congenital heart disease
- significant immunosuppression, such as from solid organ transplant, haematopoietic stem cell transplant, or primary immune deficiencies such as severe combined immunodeficiency (SCID) in consultation with a paediatric infectious disease, immunology or immunisation specialist.
- chronic lung disease requiring ongoing oxygen or respiratory support
- neurological conditions that impair respiratory function
- cystic fibrosis with severe lung disease or weight for length <10th percentile
- trisomy 21 or another genetic condition that increases the risk of severe RSV disease.

<sup>2</sup> GPs, AMSs and community health centres must use the **Nirsevimab Order Form** on the [NSW State Vaccine Centre](#) to order nirsevimab for eligible children available from 10 March 2025.

---

## Useful resources

- [NSW RSV Prevention Program – Information for health professionals](https://www.health.nsw.gov.au/immunisation/Pages/respiratory-syncytial-virus.aspx)  
<https://www.health.nsw.gov.au/immunisation/Pages/respiratory-syncytial-virus.aspx>
- [Clinical decision aid for nirsevimab \(Beyfortus™\) in newborn infants](https://www.health.nsw.gov.au/immunisation/pages/rsv-aid-infants.aspx)  
<https://www.health.nsw.gov.au/immunisation/pages/rsv-aid-infants.aspx>
- [Clinical decision aid for nirsevimab \(Beyfortus™\) in infants and children up to 24 months of age who remain at risk of severe RSV disease](https://www.health.nsw.gov.au/immunisation/pages/rsv-aid-children.aspx)  
<https://www.health.nsw.gov.au/immunisation/pages/rsv-aid-children.aspx>